Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 1, 2011, Pages 77-88

  Valkhoff, V E ^a   'T Jong, G W ^a   Van Soest, E M ^a   Kuipers, E J ^a   Sturkenboom, M C J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; RABEPRAZOLE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FEMALE; HEART INFARCTION; HIGH RISK PATIENT; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; QUANTITATIVE STUDY; RECURRENCE RISK; RECURRENT DISEASE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; CONFOUNDING FACTORS (EPIDEMIOLOGY); DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; RECURRENCE; REGRESSION ANALYSIS; RISK FACTORS; TICLOPIDINE; YOUNG ADULT;

EID: 78650011234     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04485.x     Document Type: Article

References (32)

1. Beitelshees AL, McLeod HL,. Clopidogrel pharmacogenetics: promising steps towards patient care? Arterioscler Thromb Vasc Biol 2006; 26: 1681-3.
2. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363-75.
3. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-62.
4. Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010; 121: 512-8.
5. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 2007; 102: 507-15.
6. Bhatt DL, Cryer B, Contant CF,. COGENT: A Prospective, Randomized, Placebo-Controlled Trial of Omeprazole in Patients Receiving Aspirin and Clopidogrel. Transvascular Cardiovascular Therapeutics Annual Meeting, September 2009.
7. Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Inter Med 2010; 152: 337-45.
8. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008; 118: 1894-909.
9. Food and Drug Administration. Public Health Advisory: Updated Safety Information About a Drug Interaction Between Clopidogrel Bisulfate (Marketed as Plavix) and Omeprazole (Marketed as Prilosec and Prilosec OTC). Available at:http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm190825.htm. Accessed February 6, 2010.
10. European Medicines Agency. Public Statement on Possible Interaction Between Clopidogrel and Proton-Pump Inhibitors. Available at: http://www.ema.europa.eu/humandocs/PDFs/EPAR/Plavix/32895609en.pdf. Accessed February 6, 2010.
11. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256-60.
12. Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J,. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost 2006; 4: 2508-9.
13. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374: 989-97.
14. Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009; 101: 714-9.
15. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-44.
16. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180: 713-8.
17. Pezalla E, Day D, Pulliadath I,. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors (Letter). J Am Coll Cardiol 2008; 52: 1038-9.
18. Stanek EJ, Aubert RE, Flockhart DA, et al. A National Study of the Effect of Individual Proton Pump Inhibitors on Cardiovascular Outcomes in Patients Treated With Clopidogrel Following Coronary Stenting: The Clopidogrel Medco Outcomes Study. Available at:http://wwwscaiorg/pdf/20090506Medcoabstractpdf. Accessed February 8, 2010.
19. Rassen JA, Choudhry NK, Avorn J, Schneeweiss S,. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 2009; 120: 2322-9.
20. Stockl KM, Le L, Zakharyan A, et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med 2010; 170: 704-10.
21. Suissa S,. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008; 167: 492-9.
22. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009; 373: 309-17.
23. Dunn S, Macaulay T, Brennan D, et al. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. Circulation 2008; 118: S815.
24. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment. Available at:http://www.whocc.no/atcddd. Accessed September 4, 2009.
25. Herings RM, Bakker A, Stricker BH, Nap G,. Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health 1992; 46: 136-40.
26. Richardson DB,. An incidence density sampling program for nested case-control analyses. Occup Environ Med 2004; 61: e59.
27. Indiana University SoM, Department of Medicine, Division of Clinical Pharmacology, P450 Drug Interaction Table. Available at:http://medicine.iupui. edu/clinpharm/ddis/table.asp. Accessed July 12, 2010.
28. Joffe MM, Rosenbaum PR,. Invited commentary: propensity scores. Am J Epidemiol 1999; 150: 327-33.
29. Walker AM,. Confounding by indication. Epidemiology (Cambridge, Mass) 1996; 7: 335-6.
30. Kwok CS, Loke YK,. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther 1989; 31: 810-23.
31. Charlot M, Ahlehoff O, Lykke Norgaard M, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use. Ann Intern Med 2010; 153: 378-86.
32. Stanek EJ, Aubert RE, Flockhart DA, et al. Proton Pump Inhibitors in the Absence of Clopidogrel Therapy Do Not Affect Cardiovascular Outcomes in Coronary Stent Patients. Presented at American Heart Association's Ninth Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular and Stroke. Available at:http://wwwmedcoresearchcom/servlet/JiveServlet/download/1169-6- 1082/QCOR-PPI-and-Plavix-FNLpdf. Accessed October 5, 2010.